Advertisement
Advertisement
AUTL
Autolus Therapeutics plc - ADR
1.93
USDSponsored
-0.02
-1.28%
Sep 24, 11:09 UTC -4
Open
AUTL Earnings Reports
Positive Surprise Ratio
AUTL beat 15 of 30 last estimates.
50%
Next Report
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$40.76M
/-$0.16
Implied change from Q2 26 (Revenue/ EPS)
-10.79%
/+6.67%
Implied change from Q3 25 (Revenue/ EPS)
+92.77%
/-46.67%
Autolus Therapeutics plc - ADR earnings per share and revenue
On Aug 11, 2026, AUTL reported earnings of -0.15 USD per share (EPS) for Q2 26, beating the estimate of -0.22 USD, resulting in a 31.82% surprise. Revenue reached 45.69 million, compared to an expected 34.70 million, with a 31.68% difference. The market reacted with a +12.56% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.16 USD, with revenue projected to reach 40.76 million USD, implying an increase of 6.67% EPS, and decrease of -10.79% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Autolus Therapeutics plc - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Autolus Therapeutics plc - ADR reported EPS of -$0.15, beating estimates by 31.82%, and revenue of $45.69M, 31.68% above expectations.
How did the market react to Autolus Therapeutics plc - ADR's Q2 2026 earnings?
The stock price moved up 12.56%, changed from $2.07 before the earnings release to $2.33 the day after.
When is Autolus Therapeutics plc - ADR expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Autolus Therapeutics plc - ADR's next earnings report?
Based on 5
analysts, Autolus Therapeutics plc - ADR is expected to report EPS of -$0.16 and revenue of $40.76M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.